Just think about the scores of Canadian startups and universities now engaged in some of the most exciting life sciences projects, the brilliant researchers and experts that are making headlines in their fields, and of course the entrepreneurs and investors braving the risks in order to break new ground.
Unfortunately, says biotechnology professional Tony Pullen, there is not much by way of an effective index to measure these market activities. The closest we have is the S&P/ TSX Healthcare Index, according to Pullen who has been involved in the investment business since the 1980s. Pullen provides us with a special report on the Canadian healthcare market.
His article, The Fire Marshall’s Report: A search through the embers, traces the developments in the local healthcare market from 2014 to 2016.
The world is watching Canada.
That’s because we are among the few developed countries to come up with a federal legislation on the legalization of both medical and recreational use of cannabis, according to Sabrina Ramkellawan.
The vice-president of the Clinical Research Association of Canada looks into the opportunities for Cannabis research in the country.
Ramkellawan reasons out that unlike other countries, Canada considers cannabis a Schedule II drug and cannabis is currently accessible for medical use.
This makes its clinical use easier here than in other jurisdictions.But, she says, there are several reasons why there is a lack of Canadian clinical trials in the area.
We’d also like you to check out the article by Dr. Douglas Loe. The healthcare analyst for Echelon Wealth Partners discusses cell pouch macro-encapsulation as a solution to rejection in cell therapy.
We also have an excellent article on Canada’s Vaccine and Infectious Disease Organization-International Vaccine Centre, and another piece on a new drug therapy that could treat the world’s worst infectious diseases.
If you’re in a nostalgic mood, I’d like to invite you to peruse our Biotechnology Focus 20th anniversary spread. This edition’s compilation by Shawn Lawrence covers years four through six of Biotechnology Focus.
Ulrich Krull, professor of analytical chemistry and biotechnology chair at AstraZaneca, takes us for a dip into the biotech possibilities of deep learning, machine learning, and artificial intelligence.
These trends have been making headlines in the world of technology, but in his Last Word article, Krull suggests AI, machines learning and deep learning can have a critical impact in biotechnology as well.
I hope you enjoy what we have in store for you on this issue.